China NMPA Medical Device Registration: The Complete Guide for Foreign Manufacturers

Why China Matters for Medical Device Companies

China is the second-largest medical device market in the world, valued at over $60 billion and growing at roughly 10-12% annually. For any medical device manufacturer with global ambitions, China is not optional — it is a strategic necessity.

But entering the Chinese market is fundamentally different from entering the US or the EU. The regulatory system is governed by the National Medical Products Administration (NMPA), and the process has features — mandatory in-country testing, Chinese-language dossier requirements, the Marketing Authorization Holder system — that have no direct equivalents in FDA or EU MDR pathways.

Foreign manufacturers who approach NMPA registration as "just another regulatory submission" consistently underestimate the timeline, cost, and complexity. This guide covers everything you need to know: the regulatory framework, device classification, registration pathways, documentation requirements, clinical evaluation, testing, timelines, costs, and the practical realities of navigating NMPA as a foreign manufacturer.

The Regulatory Framework: NMPA and Its Structure

The National Medical Products Administration (NMPA) — formerly the China Food and Drug Administration (CFDA) — is the national regulatory authority responsible for supervising drugs, medical devices, and cosmetics in China. The NMPA sits under the State Administration for Market Regulation (SAMR) and oversees the Center for Medical Device Evaluation (CMDE), which conducts technical reviews of device submissions.

Key Regulatory Bodies

Body	Role
NMPA	Top-level regulatory authority; issues registration certificates for Class III devices; sets national regulatory policy
CMDE (Center for Medical Device Evaluation)	Conducts technical review of Class II and III registration applications; issues review opinions
NIFDC (National Institutes for Food and Drug Control)	Oversees testing institutions; manages reference standards for medical device testing
Provincial MPAs	Register and supervise Class I and Class II devices at the provincial level; conduct post-market inspections
CDE (Center for Drug Evaluation)	Relevant for combination products (drug-device combinations)

Legal Framework

The regulatory system is built on several key legal instruments:

Instrument	Description
Regulations for the Supervision and Administration of Medical Devices (State Council Order No. 739)	The primary regulation governing medical devices in China, revised in 2021 and effective June 1, 2021. This is the "parent law" that establishes classification, registration requirements, and post-market obligations.
Administrative Measures for Medical Device Registration and Filing (NMPA Order No. 47)	Detailed procedural rules for registration (Class II/III) and filing (Class I). Revised 2021.
Administrative Measures for In Vitro Diagnostic Reagent Registration and Filing (NMPA Order No. 48)	Specific rules for IVD registration and filing. Revised 2021.
Guideline documents	CMDE publishes technical guidelines analogous to FDA guidance documents, covering specific device types, clinical evaluation, biocompatibility, software, and more.

The 2021 revision (Order No. 739) was the most significant overhaul in a decade, introducing the Marketing Authorization Holder (MAH) system, expanding priority review pathways, and aligning requirements closer to international standards.

Device Classification

China uses a three-class, risk-based classification system. Understanding your device's classification is the first step in determining your regulatory pathway.

Classification Overview

Class	Risk Level	Regulatory Pathway	Who Reviews
Class I	Low risk	Filing (Bei'an) — no technical review required	Provincial MPA
Class II	Moderate risk	Registration — technical review required	Provincial MPA (domestic) or NMPA (imported)
Class III	High risk	Registration — in-depth technical review required	NMPA

How Classification Is Determined

The NMPA maintains a Classification Catalogue (most recently updated in 2023-2024) that assigns every medical device type to a specific class. Unlike the FDA's rule-based classification or the EU MDR's Annex VIII rules, China's system is primarily catalogue-driven — you look up your device, and the catalogue tells you the class. The catalogue is organized into 22 major categories with hierarchical sub-categories covering all medical device and IVD product types.

Classification Differences from FDA and EU

Device Type	China (NMPA)	US (FDA)	EU (MDR/IVDR)
Standard surgical instruments (scalpels, forceps)	Class I	Class I (mostly exempt)	Class I (mostly)
Powered surgical instruments	Class II	Class II	Class IIa
Contact lenses	Class III	Class II (510(k))	Class IIa/IIb
Hip/knee implants	Class III	Class III (PMA) or Class II (510(k) with special controls)	Class III
Diagnostic ultrasound	Class II	Class II	Class IIa
Clinical chemistry analyzers	Class II	Class II	Class A/B (IVDR)
HIV diagnostic tests	Class III	Class II/III	Class D (IVDR)
Infusion pumps	Class II/III (depending on type)	Class II	Class IIb
AI/ML diagnostic software	Class II/III (depending on intended use)	Class II (most SaMD)	Class IIa/IIb/III (MDR Rule 11)

Critical note: Do not assume your device has the same classification in China as it does in your home market. Contact lenses, for example, are Class III in China but Class II in the US — a difference that adds years and millions of dollars to the registration process. Always verify classification through the current NMPA Classification Catalogue before planning your regulatory strategy.

Recent Classification Updates (2024-2026)

The NMPA has actively updated its Classification Catalogue: AI-enabled devices received dedicated classification guidance (Class II/III depending on clinical decision support), 3D-printed personalized devices were clarified (patient-matched implants as Class III, surgical guides as Class II), combination product rules were updated (primary mode of action determines pathway), and digital therapeutics received preliminary guidance (mostly Class II).

Registration Pathways

Class I: Filing (Bei'an)

Class I devices require only a filing — no technical review. The manufacturer submits basic product information to the provincial MPA, which issues a filing certificate within 5-10 business days.

Class II and Class III: Registration

Class II and III devices require formal registration with CMDE technical review. For imported devices, all registrations are handled at the national NMPA level. The process:

1. Appoint a Chinese authorized agent
2. Conduct required testing at NMPA-recognized institutions (or use accepted foreign reports)
3. Conduct clinical evaluation (trial, literature, or predicate comparison)
4. Prepare and submit the registration dossier (in Chinese)
5. CMDE technical review — may include supplemental information requests
6. Administrative review and certificate issuance by NMPA

Priority Review and Approval Pathways

The NMPA has established several expedited pathways to accelerate access to innovative and clinically critical devices:

Pathway	Eligibility	Benefit
Innovative Medical Device Special Review (Green Channel)	Devices with core technology that is domestically pioneered or internationally leading, with significant clinical value	Priority technical review, dedicated CMDE review team, pre-submission consultation, reduced review timelines
Priority Review	Devices that address unmet clinical needs, rare disease devices, devices for pediatric populations, or devices urgently needed during public health emergencies	Expedited review timeline (CMDE aims to complete review within 40-70 working days instead of the standard timeline)
Breakthrough Device Designation (introduced 2024-2025)	Devices representing breakthrough technology with clear clinical advantages over existing treatments	Early engagement with CMDE, rolling submission accepted, conditional approval possible

Strategy note: If your device qualifies for the Innovative Device pathway, apply early. The benefits include CMDE consultation during development, which helps avoid costly mistakes. Over 800 devices have entered this pathway, with significantly higher first-cycle approval rates.

In Vitro Diagnostic (IVD) Registration

IVD registration in China follows a parallel but distinct regulatory framework under NMPA Order No. 48. IVDs are classified under Category 21 (in vitro diagnostic reagents) and Category 22 (in vitro diagnostic instruments/equipment) in the Classification Catalogue.

IVD Classification

Class	Examples	Pathway
Class I	Microbiological culture media (non-selective), sample collection and processing devices, general laboratory equipment	Filing (Bei'an) — provincial MPA
Class II	Clinical chemistry reagents, hematology reagents, coagulation reagents, immunoassay reagents (most), microbiology identification systems	Registration — NMPA (imported)
Class III	Blood screening reagents (HIV, HBV, HCV), blood grouping reagents, genetic testing reagents, high-risk immunoassay reagents, companion diagnostics	Registration — NMPA (imported)

Key Differences from General Device Registration

IVD registration has several unique requirements:

• Reference standards: For many IVD reagents, the NIFDC provides national reference standards that must be used for performance evaluation
• Calibration traceability: Assay calibration must be traceable to recognized reference materials or reference measurement procedures
• Analytical performance studies: Specific study requirements for accuracy, precision (repeatability, reproducibility), linearity, analytical sensitivity, analytical specificity, and interference studies
• Clinical performance studies: Clinical trial or clinical evaluation comparing the device against an established method, using Chinese clinical samples
• Reagent-instrument pairing: If the IVD reagent is validated for use with a specific instrument platform, the instrument must also be registered (or be in the process of registration) in China

Companion Diagnostics (CDx)

CDx devices are classified as Class III. Clinical validation requires Chinese patient samples from the corresponding drug trial. CDx and drug reviews are coordinated but proceed on separate timelines — NMPA increasingly expects simultaneous submissions for molecular-targeted therapies.

Required Documentation: The Technical Dossier

The registration dossier for imported Class II and III medical devices is extensive. Everything must be submitted in Chinese. The dossier structure follows NMPA-specified formats, which differ from FDA and EU conventions.

Dossier Structure Overview

Section	Contents
1. Application form	Administrative information, applicant details, device identification
2. Proof of listing in country of origin	Certificate of free sale, export certificate, or equivalent from the device's home market
3. Authorization documents	Power of attorney to the Chinese authorized agent; notarized and legalized
4. Product technical requirements	Performance specifications, safety requirements, testing methods — analogous to a product specification document
5. Testing reports	Reports from NMPA-recognized testing institutions covering safety and performance per the product technical requirements and applicable Chinese national/industry standards
6. Clinical evaluation materials	Clinical trial report, clinical literature evaluation, or predicate-based clinical evaluation — per NMPA clinical evaluation guidelines
7. Product description and intended use	Detailed technical description, principles of operation, materials, intended use, indications, contraindications
8. Manufacturing information	Description of manufacturing process, quality control measures, sterilization methods (if applicable)
9. Design verification and validation	Summary of design history, verification testing, validation testing
10. Risk analysis report	Per ISO 14971 (or equivalent Chinese standard YY/T 0316)
11. Product instructions for use and labeling	In Chinese; must comply with Chinese labeling regulations and include specific content mandated by NMPA
12. Quality management system documentation	Evidence of ISO 13485 certification (or equivalent); description of QMS covering design, manufacturing, and post-market processes
13. Biocompatibility evaluation	Per GB/T 16886 series (Chinese adoption of ISO 10993)
14. Sterilization validation	If applicable; per relevant Chinese standards
15. Software documentation	If applicable; software description, software lifecycle documentation, cybersecurity documentation (per recent CMDE guidelines)
16. Other supporting materials	Any additional information requested by CMDE or relevant to the specific device type

Language and Legalization

Every document must be submitted in Chinese. Administrative documents (power of attorney, certificate of free sale) require notarization and legalization (apostille or consular legalization). A complete Class III dossier can run to thousands of pages — professional regulatory translation is essential.

Common mistake: Using general translators instead of medical device regulatory translation specialists. CMDE reviewers will reject submissions with translation errors that create ambiguity in technical claims or performance specifications.

Product Technical Requirements

This document defines the device's performance specifications and test methods. It functions as a binding standard — once accepted by CMDE, any change may require a registration change or new registration. Product technical requirements must reference applicable Chinese national standards (GB) and industry standards (YY).

Clinical Evaluation Requirements

Clinical evidence is required for all Class II and Class III medical device registrations. The level of evidence required depends on device class, novelty, and whether the device is on the NMPA's exempt list.

Clinical Evaluation Pathways

Pathway	Applicability	Description
Clinical trial in China	Required for high-risk Class III devices, novel devices, and devices without predicate equivalents	Prospective clinical trial conducted at Chinese clinical trial institutions registered with NMPA. Must follow GCP (Good Clinical Practice) and be approved by the institution's ethics committee.
Clinical literature evaluation	Available for Class II and some Class III devices with substantial published clinical evidence	Systematic review and analysis of published clinical literature demonstrating safety and effectiveness. Must follow CMDE's clinical evaluation guidelines.
Predicate-based clinical evaluation (equivalence route)	Available when a substantially equivalent device with a valid Chinese registration exists	Demonstration of substantial equivalence to a registered predicate device, supported by analytical and, if necessary, clinical data.
Exemption from clinical evaluation	Listed Class I and certain Class II devices on the NMPA's clinical evaluation exemption list	No clinical evaluation required. The exemption list is published and periodically updated by NMPA.

Clinical Trials in China

Clinical trials must be conducted at NMPA-registered institutions with ethics committee approval and GCP compliance (NMPA Order No. 54). Chinese patient enrollment is mandatory — foreign clinical data can supplement but generally cannot replace Chinese data for Class III devices. CMDE guidelines specify minimum sample sizes (60-200+ subjects for Class III implantables) and follow-up duration (12-24 months for orthopedic implants).

Acceptance of Foreign Clinical Data

The NMPA has gradually expanded its acceptance of foreign clinical data:

• Class II devices: Foreign data generally acceptable with literature analysis addressing the Chinese population
• Class III devices: Foreign data can support but usually cannot replace Chinese clinical data. CMDE typically requires a supplementary Chinese study.
• Multi-regional clinical trials (MRCTs): If the trial includes adequate Chinese enrollment (typically 20%+ or a pre-specified Chinese subgroup), MRCT data may be accepted as primary evidence

Practical guidance: The question of whether you can avoid a Chinese clinical trial is often the single biggest factor in your timeline and budget. Engage CMDE early — through pre-submission consultations or the Innovative Device pathway — to get clarity on clinical data requirements before committing to a strategy. A Class III implant clinical trial in China can cost $2-5 million and take 2-4 years. Knowing upfront whether foreign data will be accepted can save you enormous time and expense.

Clinical Evaluation Acceptance Criteria: The Equivalence Route in Detail

The predicate-based clinical evaluation (equivalence) route is the most cost-effective pathway when a substantially equivalent device already holds a valid Chinese registration. CMDE evaluates equivalence across three dimensions — closely paralleling the EU's MDCG 2020-5 framework but with China-specific requirements:

Dimension	CMDE Acceptance Criteria
Scope of application (clinical characteristics)	The subject device and the predicate must share the same intended use, indications, target population, and clinical setting. Any difference in indications requires additional supporting data or disqualifies the equivalence claim.
Technical characteristics	Design principles, key performance specifications, materials of construction, manufacturing processes, dimensions, energy source, and operating parameters must be comparable. Differences must be documented and their clinical impact assessed.
Biological characteristics	For devices with patient contact: biocompatibility profile, surface treatment, coatings, degradation characteristics, and leachables/extractables must be equivalent. Testing per GB/T 16886 series is mandatory for any material differences.

Important distinctions from FDA predicate comparison:

• CMDE's concept of "equivalent devices" is not identical to "same-type devices." The NMPA distinguishes between equivalent devices (highly comparable) and similar devices (some differences allowed but requiring bridging data). If differences exist between the subject device and the comparator, supporting materials — including laboratory testing and clinical data — must be submitted as attachments
• The predicate device must hold a valid, current Chinese registration (not just historical approval). If the predicate's registration has expired or been withdrawn, the equivalence route is generally unavailable
• For Class III devices, CMDE may require supplementary clinical data even when equivalence is demonstrated, particularly if the device contacts the body for extended duration or serves a life-sustaining function
• Authorization from the predicate device's manufacturer must be obtained if unpublished data is used in the comparison

Clinical Evaluation Exemption List Updates

The NMPA periodically publishes and updates a Catalogue of Medical Devices Exempt from Clinical Evaluation. Devices on this list can be registered without generating any clinical data, provided their safety and effectiveness can be demonstrated through non-clinical evidence alone. The exemption typically applies to products with well-established technology, mature materials, and clear mechanisms of action.

The 2025 edition (released May 13, 2025) replaced the 2023 edition and added 28 new product categories to the exemption list, including:

• Disposable endoscopic injection needles (Class III)
• Oral digital impression devices (Class II)
• Non-invasive ambulatory blood pressure recorders (Class II)
• Electromyography and evoked potential instruments (Class II)
• Telemetry monitoring systems (Class II)
• Eustachian tube balloon catheters (Class II)
• Liposuction needles (Class II)
• Temporary crown/bridge dental devices (Class II)
• Polymer-based crown/bridge materials for CAD/CAM (Class III)

Practical impact: If your device falls within a newly exempted category, the registration timeline and cost can drop dramatically — eliminating the need for a clinical trial or clinical evaluation report. Check the current exemption list early in your regulatory planning and confirm applicability with your authorized agent, as the exemption criteria require demonstrating comparability to the catalogue description across intended use, composition, mechanism of action, manufacturing materials, functional specifications, sterilization method, and operation method.

CMDE Clinical Trial Inspection Standards (2025)

In 2025, the NMPA published updated inspection points for medical device clinical trials. The inspection framework classifies findings into three tiers:

Finding Level	Description	Consequence
Serious non-compliance	Modification of data, untraceability of key activities, incomplete/inconsistent data, refusal to cooperate with inspections	Registration application denied (pre-market) or safety studies initiated with corrective measures (post-market)
Normative issue	Process flaws that do not affect safety and efficacy conclusions	NMPA continues review without penalty
Compliance	No issues identified	No action

These criteria are relevant to both Chinese clinical trials and to foreign clinical data submitted in support of NMPA registrations, as they reflect core data integrity principles shared with FDA and other major regulatory authorities. Manufacturers should ensure their clinical trial sites — whether in China or abroad — maintain full-chain compliance with these standards.

Clinical Evaluation Reform (2024-2026)

Recent reforms have expanded pathways to leverage existing clinical evidence: CMDE published RWE guidelines in 2024 supporting device registrations and expanded indications; equivalence pathway criteria were clarified in 2025 for Class II and lower-risk Class III devices; and a conditional approval pathway now allows breakthrough devices to reach market based on early clinical evidence with post-market confirmatory studies.

Testing Requirements

In-Country Testing

One of the most distinctive features of China's medical device registration system is the requirement for product testing at NMPA-recognized testing institutions within China. This has historically been one of the most time-consuming steps in the registration process.

What Testing Is Required?

Testing covers two broad categories:

1. Safety testing: Electrical safety (per GB 9706 series, which adopts IEC 60601 with national deviations), electromagnetic compatibility (per GB/T 18268 or GB 4824), and other applicable safety standards
2. Performance testing: Per the product technical requirements and applicable Chinese national/industry standards

Specific CMDE Testing Requirements by Device Category

CMDE publishes device-specific technical review guidelines that define the minimum testing expectations for each product category. Understanding these requirements before submitting samples is critical to avoiding re-testing.

Device Category	Key CMDE Testing Requirements
Active medical equipment (electrical)	Full GB 9706.1-2020 (IEC 60601-1 Ed. 3.1) safety testing, applicable particular standards (GB 9706.2xx series), EMC per YY 9706.102, environmental testing per GB/T 14710-2009 (temperature, humidity, vibration, transport simulation)
Implantable devices	Biocompatibility per GB/T 16886 series (ISO 10993 adopted), mechanical/fatigue testing per device-specific YY standards, accelerated aging/shelf-life studies, sterilization validation per GB 18279/GB 18280
Software/SaMD	Software lifecycle documentation per YY/T 0664 (based on IEC 62304), software description document, cybersecurity testing per CMDE cybersecurity guidelines (2024), algorithm validation for AI/ML devices including training data requirements and bias analysis
IVD reagents	Analytical performance (accuracy, precision, linearity, analytical sensitivity/specificity, interference, hook effect) per CMDE IVD guidelines, reference interval verification using Chinese population samples, stability studies (real-time and accelerated), calibration traceability to NIFDC reference standards where applicable
Sterile devices	Sterilization validation (EO, radiation, or steam per applicable GB standards), package integrity testing per GB/T 19633, bioburden testing, residual EO limits per GB/T 16886.7
Combination products	Testing requirements from both device and drug regulatory tracks as applicable; primary mode of action determines lead review pathway

Standards alignment note: As of 2025, China maintains over 2,082 valid medical device standards — an 18.4% increase compared to 2020. The consistency rate between Chinese and international medical device standards reached 93% in 2025, which lowers technical barriers for manufacturers already aligned with IEC/ISO norms. However, the remaining 7% of national deviations — particularly in electrical safety, EMC, labeling, and certain biocompatibility test protocols — can still trigger re-testing requirements. Always map your existing test evidence against the specific GB/YY standards before assuming transferability.

GB 9706.1-2020 Transition: What You Need to Know

China's adoption of IEC 60601-1 Edition 3.1 resulted in GB 9706.1-2020, published April 9, 2020, which took effect on May 1, 2023. The transition has significant implications:

• New registrations: All new registration applications for active medical equipment must comply with GB 9706.1-2020 and applicable particular standards (GB 9706.2xx series)
• Existing registrations: Registered active medical devices had until approximately May 1, 2026 (three-year transition from effective date) to demonstrate compliance with the new standard, though the exact deadline varies depending on specific sub-standards — manufacturers must consult the applicable particular standard implementation dates for their product
• Key differences from IEC 60601-1: GB 9706.1-2020 is largely equivalent to IEC 60601-1 Ed. 3.1 but includes national deviations for power supply (220V/50Hz), Chinese-language labeling of safety markings, and specific clauses adapted for the NMPA testing institution framework
• Impact on foreign manufacturers: Companies already complying with IEC 60601-1 Ed. 3.1 internationally face a smaller gap than domestic manufacturers transitioning from the older GB 9706.1-2007 (based on IEC 60601-1 Ed. 2). However, testing must still be completed at NMPA-recognized labs against the GB standard specifically, and national deviations must be addressed
• Inspection reports: Must be issued by qualified medical device inspection agencies with the appropriate scope and CMA (China Inspection Body and Laboratory Mandatory Approval) accreditation to evaluate compliance with GB 9706.1-2020 and its related standards

Self-Testing: An Emerging Alternative to In-Country Testing

The 2021 reform (State Council Order No. 739 and NMPA Announcement No. 126/2021) introduced the option for manufacturers to submit self-testing reports in lieu of testing at an NMPA-recognized Chinese lab. In September 2025, the NMPA released detailed Guidelines for Self-Inspection and Verification of Medical Device Registration, further formalizing this pathway.

Key requirements for self-testing:

• The manufacturer's laboratory must have a quality management system meeting NMPA verification standards
• Qualified testing personnel with documented training and competency records are required
• Equipment and facilities must meet the environmental and technical requirements of each test method
• Documented procedures for sample management, traceability, and quality control must be established
• Participation in proficiency testing or inter-laboratory comparisons is encouraged to confirm technical competence
• For non-standard methods or modifications of recognized standards, a Method Confirmation Report must be prepared covering accuracy, precision, linearity, detection limits, and robustness

For overseas manufacturers specifically:

• Manufacturers outside China may use their own accredited laboratories or laboratories within their corporate group, provided the lab is accredited by a foreign government or its recognized accreditation body
• Proper authorization documentation and evidence that testing falls within the laboratory's accredited scope must be submitted
• Provincial drug authorities may verify self-inspection through document review or on-site inspection (on-site review is generally required unless the lab has existing CNAS accreditation)
• Practical reality: Despite the regulatory opening, NMPA reviewers and testing institutions retain significant discretion. Most regulatory consultants still recommend in-country testing at an NMPA-recognized lab as the lowest-risk path, particularly for first-time registrations. Self-testing is most viable for established manufacturers with a strong compliance track record in China

NMPA-Recognized Testing Institutions

There are approximately 30+ NMPA-recognized medical device testing institutions across China. The most commonly used include:

Institution	Location	Notes
CMDE-affiliated institutions	Beijing	Direct affiliation with the review center
Shanghai Medical Device Testing Institute	Shanghai	One of the largest and most experienced
Shandong Medical Device Testing Center	Jinan	Strong in certain device categories
Guangdong Medical Device Quality Inspection Institute	Guangzhou	Major testing center in southern China
Tianjin Medical Device Testing Center	Tianjin	Established institution in northern China

Testing Timelines

Testing timelines vary significantly by device type and complexity:

Device Type	Typical Testing Duration
Simple Class II devices (non-electrical)	2-4 months
Powered/electrical Class II devices	4-8 months
Complex Class III devices	6-12 months
Software-based devices	3-6 months (plus cybersecurity review if applicable)
IVD reagents	3-8 months (depending on assay complexity)

Acceptance of Foreign Test Reports

Historically, all testing had to be conducted in China. Recent reforms (2024-2026) have changed this:

• Mutual recognition of test reports: For certain device categories, NMPA now accepts test reports from ILAC MRA-accredited laboratories outside China that test to applicable Chinese standards
• Pilot programs in free trade zones: Hainan, Greater Bay Area, and Beijing have expanded acceptance of foreign test data
• Supplemental testing model: Foreign test reports may be accepted for some test items, while Chinese labs conduct supplemental testing for items with national deviations

Important caveat: Even where foreign test reports are theoretically accepted, Chinese testing institutions and CMDE reviewers retain discretion. Many manufacturers find that submitting testing to a Chinese lab remains the safest path to avoid review delays.

EMC and Electrical Safety: Chinese National Deviations

China has adopted many IEC standards but with national deviations. GB 9706.1 (based on IEC 60601-1) includes deviations for power supply requirements (220V/50Hz) and labeling. EMC testing must account for China's power grid characteristics. Software standards follow YY/T 0664 (based on IEC 62304) with additional CMDE-specific requirements for AI/ML-enabled devices.

The Marketing Authorization Holder (MAH) System

The Marketing Authorization Holder system, introduced in the 2021 reform, makes the registration certificate holder legally responsible for the device throughout its entire lifecycle. Before 2021, the certificate was tightly coupled to the manufacturing site. The reform decoupled ownership and manufacturing, enabling contract manufacturing arrangements.

For foreign manufacturers: you remain the MAH for imported devices. Your Chinese authorized agent acts on your behalf but does not replace you. Legal liability for product safety, adverse events, and post-market obligations rests with you. A foreign manufacturer can also contract manufacturing to a Chinese facility and register as a domestic product, though this requires careful structuring.

MAH Responsibilities

Obligation	Description
Product quality	The MAH is responsible for ensuring the device meets its registered product technical requirements throughout its commercial life
Adverse event monitoring and reporting	The MAH must establish an adverse event monitoring system and report adverse events to the NMPA per applicable timelines
Post-market surveillance	The MAH must conduct ongoing PMS, including complaint handling, trend analysis, and periodic safety update reporting
Recalls	The MAH is responsible for initiating and managing device recalls when safety issues are identified
Traceability	The MAH must maintain records enabling full traceability of the device through the supply chain
Annual reporting	The MAH must submit annual self-inspection reports and other periodic reports to the provincial MPA

MAH and Contract Manufacturing: How It Works in Practice

The MAH system fundamentally changed the relationship between registration and manufacturing in China. Before 2021, the registration certificate was tightly coupled to the manufacturing site. The reform decoupled these, enabling several new arrangements:

For foreign manufacturers considering domestic production:

• A foreign MAH can contract a qualified Chinese manufacturer to produce devices domestically while retaining the registration certificate
• NMPA Announcement No. 30 (March 2025) significantly expanded the eligibility for domestic production of imported devices. Previously, only foreign-invested enterprises (FIEs) directly established by the original registrant were eligible. The updated policy now includes enterprises that share the same "actual controller" as the original registrant — broadening the pool of entities that can qualify for localized manufacturing
• For Class II and Class III devices with imported registration certificates, the domestic investor enterprise or another domestic enterprise sharing the same actual controller may serve as the registration applicant for the locally manufactured product
• The original registration application materials submitted for the imported device are recognized by the NMPA for the domestic registration, provided the design is unchanged, the quality system is basically consistent, and safety and effectiveness are not significantly altered — eliminating the need to completely redo non-clinical research, testing, and clinical evaluation
• Key restriction: High-risk implantable medical devices must still be manufactured by the MAH itself and cannot be fully delegated to a contract manufacturer

MAH obligations in contract manufacturing arrangements:

• The MAH must conduct a full assessment of the contract manufacturer before engagement
• Regular audits of the production site are required
• The MAH must implement effective quality control measures and promptly communicate production changes to the contracted party
• A formal quality agreement defining responsibilities is required
• The contract manufacturer must demonstrate independent quality accountability under the MAH's oversight

Strategic consideration: The MAH system opens significant opportunities for cost optimization and supply chain resilience by enabling localized production. However, the MAH retains full legal liability regardless of the manufacturing arrangement. Foreign companies using this pathway must invest in robust quality oversight of their Chinese manufacturing partners — NMPA inspectors will hold the MAH accountable for any quality failures, not the contract manufacturer.

Revised GMP for Medical Devices (November 2025)

On November 4, 2025, the NMPA published its revised Good Manufacturing Practice for Medical Devices, the most comprehensive restructuring of China's device GMP framework since 2014. The revised GMP takes effect on November 1, 2026, giving manufacturers one year to adapt.

Key changes:

• Expanded scope: Now explicitly applies to MAHs, filing applicants, and all entities involved in contract manufacturing — emphasizing full supply-chain responsibilities
• New chapters: Three new chapters added — Quality Assurance, Verification and Validation, and Contract Manufacturing and Outsourcing (expanding from 10 chapters/65 articles to 15 chapters/131 articles)
• Lifecycle quality management: Strengthened emphasis on risk-based quality management from design through post-market, aligned with ISO 13485, EU MDR, and FDA QMSR/21 CFR 820 concepts
• Digital transformation: New requirements for digital and intelligent manufacturing systems, including electronic records and data integrity provisions
• Contract manufacturing governance: Detailed provisions requiring the entrusting party (MAH) to conduct full assessments of contract manufacturers, perform regular production site audits, and maintain effective change communication

Impact on foreign manufacturers: Even for devices manufactured abroad, NMPA reviewers increasingly expect consistent quality-system logic and documentation — especially in design controls, risk management, and CAPA. Understanding the revised GMP helps foreign companies anticipate reviewer questions and avoid registration deficiencies.

Chinese Authorized Agents (In-Country Representatives)

Foreign manufacturers cannot directly register medical devices with the NMPA. You must appoint a Chinese authorized agent — a legal entity registered in mainland China — to submit registration applications, manage CMDE communication, coordinate testing, handle post-market reporting, and ensure Chinese-language compliance on your behalf.

Choosing the Right Agent

This is one of the most consequential decisions in your China market entry strategy. Key selection criteria:

• Regulatory expertise: Demonstrated experience with your device type and CMDE review expectations
• Relationships and reputation: Track record with CMDE reviewers, testing institutions, and provincial MPAs
• Technical capability: Ability to handle product technical requirements, clinical evaluation, and CMDE deficiency letter responses
• Communication: Effective English communication with your team while managing all Chinese-language interactions
• Post-market support: Capability to support registration renewals, supplemental applications, and ongoing compliance
• Independence: Some agents are also distributors — understand the implications before combining these roles

Warning: Changing your authorized agent mid-registration is possible but painful. It requires re-submission of authorization documents, potential re-legalization, and can set your timeline back by months. Choose carefully upfront.

Registration Timeline and Costs

Realistic Timelines

The timelines below reflect total elapsed time from preparation start to certificate issuance for imported devices, assuming no major deficiencies.

Phase	Class II (typical)	Class III (typical)
Agent appointment and preparation	1-2 months	1-2 months
Product testing (in China)	3-8 months	6-12 months
Clinical evaluation/trial	0-6 months (if literature-based)	6-36 months (if clinical trial required)
Dossier preparation and translation	2-4 months	3-6 months
CMDE technical review	4-8 months	6-18 months
Supplemental information response cycles	0-6 months	2-12 months
Administrative review and certificate issuance	1-2 months	1-3 months
Total (estimated range)	12-24 months	24-60 months

For Class III devices requiring a Chinese clinical trial, total timelines of 4-5 years from project initiation to registration certificate are common. For Class II devices where foreign clinical data and test reports are accepted, timelines closer to 12-18 months are achievable.

CMDE Official Review Timelines (Working Days)

Understanding the CMDE's statutory review timelines helps set expectations and identify when delays may indicate issues:

Phase	Class II (Imported)	Class III (Imported)
Acceptance review (completeness check)	~5 working days after electronic dossier submission via eRPS	~5 working days
NMPA administrative timeline	~35 working days	~35 working days
First CMDE technical review	60 working days	90 working days
Supplementary notice response window	Maximum 1 year from receipt of supplementary notice	Maximum 1 year from receipt
Second CMDE technical review (after supplementary response)	60 working days	60 working days
Administrative evaluation	20 working days	20 working days
Certificate issuance	10 working days	10 working days

Note on the eRPS system: Medical device registration in China can now be completed through the NMPA's Electronic Registration Platform System (eRPS), via in-person submission, or by postal mail. The eRPS system has been progressively expanded and is now the standard channel for all new applications, change registrations, and renewals. NMPA provides the acceptance review within the first 5 working days after electronic submission — if deficiencies in completeness are found, a notification letter is issued, which increasingly may also flag technical issues at this early stage (a practice that became more common from 2019 onward).

Registration Costs

Costs vary significantly based on device class, testing requirements, and clinical evaluation approach.

NMPA Government Registration Fees (Official Fee Schedule)

The NMPA charges standardized application fees based on device classification and registration type. These fees are payable in RMB upon acceptance of the application:

Fee Type	Class II (Imported)	Class III (Imported)	Class III (Domestic)
Initial registration	210,900 RMB (~$29,000 USD)	308,800 RMB (~$43,000 USD)	153,600 RMB (~$21,000 USD)
Change registration	42,000 RMB (~$5,800 USD)	50,400 RMB (~$7,000 USD)	50,400 RMB (~$7,000 USD)
Renewal registration (5-year)	40,800 RMB (~$5,600 USD)	40,800 RMB (~$5,600 USD)	40,800 RMB (~$5,600 USD)
Clinical trial application (high-risk)	—	43,200 RMB (~$6,000 USD)	43,200 RMB (~$6,000 USD)

International comparison: China's government registration fee for a Class II imported device (210,900 RMB / $29,000 USD) is the highest among major markets for comparable risk classes — higher than an FDA 510(k) ($21,000 USD), Canada Class II ($9,000 USD), or Japan Class III ($3,500 USD). However, the government fee remains a small fraction of the total registration cost.

Total Cost Breakdown

Cost Component	Estimated Range (USD)
Authorized agent fees	$30,000-$80,000/year (varies by scope of services)
Product testing (in China)	$5,000-$20,000 per device family for routine testing; $15,000-$100,000+ for complex devices requiring multiple test standards
Clinical trial (if required)	$500,000-$5,000,000+ (Class III implants at the high end)
Dossier preparation and translation	$30,000-$150,000
NMPA registration fees (government)	210,900-308,800 RMB ($29,000-$43,000 USD) for initial registration
Notarization and legalization	$5,000-$15,000
Total (Class II, no clinical trial)	$80,000-$250,000
Total (Class III, with clinical trial)	$800,000-$5,000,000+

Budget reality: The government registration fees are a small fraction of the total cost. The real expenses are testing, clinical trials, and the ongoing authorized agent relationship. Many foreign manufacturers are surprised that China's registration costs for a Class III device can rival or exceed FDA PMA costs — without accounting for the opportunity cost of a longer timeline.

Registration Certificate Validity and Renewal

• Registration certificates are valid for 5 years
• Renewal applications must be submitted 6 months before expiration
• Renewal requires demonstration of continued compliance, including updated post-market surveillance data
• If the registration certificate expires before renewal is granted, the device cannot be legally marketed in China during the gap period

Post-Market Requirements

Adverse Event Monitoring and Reporting

The MAH must establish an adverse event monitoring system. Reporting timelines are as follows:

Event Type	Reporting Timeline
Death or serious injury	Report to the provincial MPA and NMPA within 15 calendar days of becoming aware
Device malfunction that could lead to death or serious injury	Report within 15 calendar days
Cluster events (same or similar adverse events involving the same device model)	Report within 15 calendar days of becoming aware of the cluster
Other reportable events	Report within 30 calendar days

The NMPA's Center for ADR Monitoring (CADERM) oversees the national adverse event monitoring database. Foreign manufacturers fulfill their reporting obligations through their Chinese authorized agent.

Post-Market Surveillance (PMS) and Periodic Safety Update Reports (PSURs)

The 2021 regulatory reform significantly strengthened post-market surveillance requirements:

• PMS plan: The MAH must establish and maintain a PMS plan covering complaint handling, adverse event monitoring, literature monitoring, and proactive data collection
• Annual PMS report: Required for all registered devices
• Periodic Safety Update Report (PSUR): Required for Class III devices and Class II devices where NMPA specifically requires it. PSURs must be submitted annually for the first three years after registration, then every five years thereafter (unless otherwise specified).

Quality Management System Inspections

The NMPA may conduct on-site QMS inspections at the foreign manufacturer's facility, both pre-market (particularly for Class III devices) and post-market (routine or for-cause). Inspections cover design controls, manufacturing, CAPA, complaint handling, and traceability, referencing ISO 13485 and Chinese GMP requirements. These inspections have become more common since 2021.

NMPA vs. FDA vs. EU MDR: A Comparative Overview

Aspect	China (NMPA)	US (FDA)	EU (MDR)
Regulatory authority	NMPA (national); provincial MPAs (Class I/II domestic)	FDA (federal)	Competent Authorities (national) + Notified Bodies
Classification	3 classes (I, II, III) — catalogue-based	3 classes (I, II, III) — product code/panel-based	4 classes (I, IIa, IIb, III) — rule-based (Annex VIII)
Pre-market pathway	Filing (Class I), Registration (Class II/III)	510(k), De Novo, PMA	Self-declaration (Class I), Notified Body conformity assessment (IIa-III)
Clinical evidence	Clinical trial, literature, or equivalence; Chinese clinical data often required for Class III	Clinical trial or literature depending on pathway; no geographic restriction on trial location	Clinical evaluation mandatory for all classes; clinical investigations for implants/Class III unless justified
Product testing	Must be conducted at NMPA-recognized labs (with expanding acceptance of foreign reports)	Accredited labs acceptable (no geographic restriction)	Accredited labs acceptable (no geographic restriction)
In-country representative	Mandatory Chinese authorized agent	US Agent required for foreign manufacturers	EU Authorized Representative required for non-EU manufacturers
Language	Chinese (all documents)	English	Language of the member state(s) where marketed
Certificate validity	5 years (renewable)	No expiration (510(k)); annual reporting (PMA)	5 years (renewable)
Review timeline	12-60 months (total process)	3-12 months (510(k)/De Novo); 12-18 months (PMA)	Variable (depends on Notified Body capacity); 6-24 months typical
UDI	UDI system being implemented (phased rollout, aligned with IMDRF framework)	Mandatory UDI	Mandatory UDI (phased by class)
Post-market surveillance	PMS plan, adverse event reporting, PSUR (Class III)	MDR (Medical Device Reporting), corrections/removals	PMS plan, PMCF, PSUR/periodic safety update report
QMS inspection	NMPA on-site inspection (foreign or domestic)	FDA establishment inspection (domestic and foreign)	Notified Body QMS audit (Annex IX)

Free Trade Zones and Pilot Programs

China has established several free trade zones and pilot areas that serve as testbeds for policies that often become national standards.

Hainan Boao Lecheng International Medical Tourism Pilot Zone

The Boao Lecheng zone, established in 2013 on the island of Hainan, is China's most significant pilot zone for medical device market access. It operates under special State Council authorization that suspends certain provisions of the standard medical device regulations:

• Urgent-need import authorization: Medical devices approved overseas but not yet registered with the NMPA can be imported and used at designated hospitals within the zone, provided they already have home country approval, are urgently needed for clinical use, and no equivalent product is registered in China
• Hospital-initiated process: The hospitals within the pilot zone submit the import application to the Hainan provincial MPA — the manufacturer cannot apply directly. This distinguishes Boao Lecheng from standard NMPA registration, where the manufacturer (through its agent) initiates the process
• Real-world data collection for national registration: Data from device use in Boao Lecheng can be used to support subsequent national NMPA registration applications. The manufacturer should apply to the NMPA for real-world data approvals in parallel with the hospital's import application. The NMPA evaluates two key criteria: the product should be urgently needed for clinical use, and there should be no products of the same variety already registered in China
• Track record: Since the pilot zone commenced, over one hundred urgently-needed imported medical devices have been accepted. The first non-Chinese device to successfully leverage this pathway — a glaucoma drainage tube manufactured by US company Allergan — obtained full NMPA approval for nationwide sales in March 2020, using real-world data obtained within the zone supplemented by clinical data from outside China
• Mandatory registration timeline: If an imported device has been used in the zone for a certain period, the Hainan provincial MPA will direct the overseas manufacturer to apply for national NMPA registration. If the registration application is not submitted on time, further import and use under the urgent-need pathway is stopped
• Streamlined import procedures: Simplified customs and import approval within the zone

Greater Bay Area (Guangdong-Hong Kong-Macao)

The GBA program enables certain Hong Kong- or Macao-registered medical devices to be used in designated mainland hospitals without NMPA registration. However, this pathway operates differently from any other market access mechanism in China:

• Hospital-requested permission, not manufacturer-driven: Under the GBA program, the manufacturer cannot apply. Only a designated mainland hospital can petition the Guangdong Provincial MPA to use a Hong Kong/Macao device. The hospital must demonstrate an unmet clinical need — the product must be urgently needed and no similar product should be available in mainland China
• Limited geographic scope: The program covers nine mainland cities in the Greater Bay Area: Guangzhou, Shenzhen, Zhuhai, Foshan, Huizhou, Dongguan, Zhongshan, Jiangmen, and Zhaoqing
• One-year, single-institution authorization: Permission is valid for one year and only for the specific requesting institution. It is not a substitute for NMPA registration and cannot be used for general commercial sales
• Contract manufacturing enablement: After obtaining an imported medical device registration certificate from NMPA, Hong Kong and Macao registrants can entrust qualified manufacturers in the nine GBA mainland cities to produce the devices domestically
• MAH flexibility: If the MAH is a Hong Kong or Macao enterprise, it can appoint an enterprise in the GBA to perform its MAH duties, though the appointed GBA enterprise bears joint and several liabilities
• Cross-border clinical trial coordination: The GBA program facilitates clinical trial coordination between Hong Kong/Macao and mainland institutions

Beijing Pilot Programs

• Acceptance of foreign test reports from ILAC-accredited laboratories for selected device categories
• Streamlined registration procedures for AI-enabled medical devices
• Pilot programs for conditional approval of breakthrough devices

Shanghai Pilot Programs

• Acceptance of overseas clinical trial data for certain device categories
• Simplified re-registration procedures for devices with good post-market records
• MAH system pilot programs (Shanghai was one of the earliest MAH pilot areas)

Strategic opportunity: The Hainan Boao Lecheng pathway is particularly attractive for Class III innovative devices. You can generate Chinese real-world data and build KOL relationships while pursuing national NMPA registration — entering the market years ahead of a traditional registration-only strategy.

Recent Regulatory Reforms (2024-2026)

NMPA Registration Activity: 2025 Data

The NMPA's 2025 Annual Report on Medical Device Registration provides the clearest picture of regulatory throughput and market dynamics:

Metric	2025 Data	Year-on-Year Change
Total approvals	14,187	+8%
Imported device approvals	6,040 (42.6% of total)	+6.5%
Applications accepted	14,647	+5.9%
Innovative devices approved	76	+17%
Priority review approvals	25	+212.5%

Imported device registration breakdown:

• First-time registrations: 642 (Class II: 270; Class III: 372), accounting for 10.6% of imported approvals
• Renewals: 2,600 (Class II: 1,450; Class III: 1,150), accounting for 43.0%
• Modifications: 2,798 (Class II: 1,382; Class III: 1,416), accounting for 46.4%

The relatively small share of first-time approvals indicates a mature installed base of imported devices, while the dominance of renewals and modifications reflects active lifecycle management. Products from 30 countries were approved in 2025, with the top five countries accounting for more than 75% of first-time registrations.

Category trends: Dental devices became the top category (up 24% year-on-year), ophthalmic devices recorded the fastest growth (up 35.2%), and medical imaging devices entered the top five for the first time. Some traditional categories — including passive implants — showed slower growth, likely due to increasing domestic substitution and volume-based procurement pressures.

2024 Reforms

• Expanded acceptance of foreign test reports: NMPA issued guidance broadening the circumstances under which foreign laboratory test reports are accepted, reducing the need for redundant in-country testing for certain device categories
• AI/ML medical device guidance: CMDE published comprehensive technical guidance for AI-enabled medical devices, covering algorithm transparency, training data requirements, algorithm change protocols, and cybersecurity. From 2020 through mid-2025, a total of 154 AI-based medical devices were approved, with annual approvals growing from 9 in 2020 to 45 in 2024 (a 49.5% compound annual growth rate). Most AI devices (79.9%) were classified as Class III, with radiology dominating (68.8% of approvals)
• Real-world evidence guidelines: Updated guidelines expanding the use of real-world data to support device registrations, supplemental applications, and expanded indications
• Clinical evaluation guideline updates: Revised clinical evaluation guidelines making it easier to leverage foreign clinical data for Class II devices and clarifying equivalence criteria. CMDE added 25 devices to the "Guidelines for Deciding Whether to Conduct Clinical Trials on Medical Devices"
• UDI implementation acceleration: Phase 2 of China's UDI system rollout, extending mandatory UDI requirements to additional Class II device categories. Pilot programs in Tianjin, Shanghai, Fujian, and Hainan provinces have tested "one-code connectivity" systems linking UDI to hospital procurement, insurance, and patient traceability
• New IVD Classification Catalog: CMDE released a new IVD Classification Catalog (effective January 1, 2025) assigning structured coding (6840-XX primary codes with XX-XXXX sub-category codes) to in vitro diagnostic reagents based on intended use and diagnostic function
• Draft Medical Device Administrative Law: In September 2024, the NMPA released a draft version of a new Medical Device Administrative Law (MDAL) that proposed eliminating the requirement that imported medical devices must have home-country market approval before submission to NMPA. If finalized, this would be one of the most transformative changes in China's medical device regulatory history, enabling manufacturers to pursue China as a first market

2025 Reforms

• Breakthrough Device Designation program: Formalization of the breakthrough device pathway, offering early CMDE engagement, rolling submissions, and conditional approval
• CMDE implementation rules for innovative and priority review (effective April 18, 2025): New rules enable earlier engagement with CMDE, accelerate timelines, and enhance transparency via the eRPS system. International manufacturers should note localized clinical data requirements, patent validity constraints, and product classification criteria
• High-End Medical Device Priority Approval Catalog (2025 Edition): The NMPA published a formal catalog of high-end medical devices eligible for priority approval under NMPA Announcement No. 63 of 2025, covering categories including advanced imaging systems, AI-enabled diagnostic devices, and innovative implants
• E-labeling (electronic IFU) expansion: Updated guidance allowing broader use of electronic instructions for use, reducing the burden of Chinese-language labeling for frequently updated software-based devices
• Domestic production of imported devices (Announcement No. 30): Expanded eligibility for localized manufacturing of imported devices (detailed in the MAH section above)
• Self-inspection guidelines (September 2025): Formalized requirements for manufacturer self-testing (detailed in the Testing section above)
• Revised GMP (November 2025): Comprehensive overhaul of manufacturing quality requirements, effective November 1, 2026 (detailed in the MAH section above)
• Post-market surveillance streamlining: Updated PSUR requirements, reducing reporting burden for devices with good post-market safety records. Pilot programs for active post-market surveillance focusing on high-risk categories such as cardiovascular implants, including dedicated databases to track device performance
• International regulatory cooperation: Expanded participation in IMDRF work items; increased acceptance of MDSAP audit reports as supplementary evidence of QMS compliance. China launched the Malaysia-China Medical Device Regulatory Reliance Program (Pilot Phase I) in July 2025 — the first reciprocal arrangement under the Global Harmonization Working Party (GHWP), focused on IVD devices, enabling NMPA "Green Channel" access for Malaysian-approved IVDs and reciprocal verification pathway access for Chinese products
• Cybersecurity requirements formalization: Mandatory cybersecurity technical review requirements for connected medical devices and SaMD, with specific documentation requirements for pre-market submissions
• 38 new medical device standards: NMPA issued 38 new medical device standards across multiple categories (dentistry, implants, IVDs, imaging, software, sterilization, robotics), including YY/T 1960-2025 as the core labeling framework. Manufacturers must plan type testing and submissions accordingly, as Chinese labs and reviewers immediately transition to the latest editions
• Standards system growth: By end of 2025, China maintained 2,082 valid medical device standards (up 18.4% from 2020), with 93% consistency between Chinese and international standards. The number of national standardization technical organizations increased to 39 (up 18.2%)

2026 Reforms (In Progress)

• Further expansion of foreign test report acceptance: Proposed broadening of the device categories and test standards eligible for foreign report acceptance
• Clinical trial reform: Proposed measures to reduce the requirement for separate Chinese clinical trials when adequate multi-regional clinical trial data exists with sufficient Chinese patient enrollment
• Harmonization with IMDRF standards: Continued alignment of Chinese technical standards with international consensus, including updates to the Classification Catalogue and product technical requirement templates. NMPA plans to revise 80 medical device industry standards in 2026, spanning orthopedics, cardiovascular devices, and advanced diagnostics
• Digital health regulatory framework: Development of a comprehensive regulatory framework for digital therapeutics, remote monitoring devices, and health AI applications
• Revised GMP implementation (November 1, 2026): All domestic and overseas MAHs, filing applicants, and contract manufacturers must comply with the revised Good Manufacturing Practice for Medical Devices
• New biomedical technology regulation (effective May 1, 2026): The "Administrative Regulation on Clinical Research and Clinical Transformation of New Biomedical Technologies" applies to all projects conducted within China, including those by foreign-invested institutions, establishing a unified management framework for cutting-edge biomedical technologies

Overall trajectory: The direction is clear — greater international alignment, expanded acceptance of foreign data, and faster innovation pathways. But reforms are incremental. Verify the current implementation status of any reform before relying on it in your strategy.

Practical Tips for Foreign Manufacturers

Before You Start

1. Verify your classification first. Use the current NMPA Classification Catalogue. Do not rely on your FDA or EU classification — China's classification can be higher or lower, and the difference fundamentally changes your timeline and budget.

2. Understand whether a clinical trial will be required. This single factor can add 2-4 years and millions of dollars. Use CMDE pre-submission consultations and review the clinical evaluation exemption list early.

3. Budget realistically. Class III registration in China is a multi-year, multi-million-dollar project. Class II registration is faster and cheaper but still requires significant investment. Do not approve a China market entry project based on optimistic assumptions.

4. Choose your authorized agent carefully. Interview multiple candidates. Ask for references from other foreign manufacturers in your device category. Evaluate technical depth, not just price.

5. Secure executive commitment. China registration is a marathon, not a sprint. Projects that lose executive support mid-stream (because timelines are longer than initially promised) tend to fail. Set realistic expectations from the outset.

During Registration

6. Prepare your documents to Chinese standards from the beginning. Do not repurpose your FDA 510(k) summary or EU technical documentation and expect it to pass CMDE review. The dossier structure, content expectations, and level of detail are different.

7. Invest in high-quality regulatory translation. Technical accuracy in Chinese regulatory terminology is non-negotiable. Use translators with medical device regulatory experience, not general medical translators.

8. Manage testing proactively. Engage the testing institution early, confirm sample requirements and test standards before shipping samples, and monitor testing progress regularly. Testing delays are the most common source of timeline slippage.

9. Respond to CMDE deficiency letters promptly and thoroughly. CMDE typically allows a limited response window (often 4-6 months). Responses that are incomplete or that fail to address the reviewer's specific concern result in additional review cycles, each adding months to the timeline.

10. Keep your home-market registration current. The certificate of free sale or proof of home-market listing is a required component of the Chinese dossier. If your home-market registration lapses or is modified, it can affect your Chinese registration.

Common Mistakes to Avoid

Mistake	Consequence
Assuming China classification matches FDA/EU classification	Wrong regulatory pathway; wasted time and money
Underestimating the timeline for Class III registration	Missed market windows; competitive disadvantage
Choosing the cheapest authorized agent instead of the most qualified	Poor-quality submissions; extended review cycles; failed registrations
Submitting foreign test reports without confirming acceptance	Testing rejected; need to re-test in China; 6-12 month delay
Failing to plan for Chinese clinical trial requirements	Year-long delays when CMDE requires Chinese clinical data
Using general translators instead of regulatory specialists	Ambiguous translations flagged by CMDE; deficiency letters
Neglecting post-market obligations after registration	Non-compliance findings; risk to registration renewal
Changing authorized agent mid-registration	Re-submission of authorization documents; months of delay
Starting with a Class III device instead of building experience with a simpler product	Steep learning curve on the most complex pathway
Ignoring pilot zone opportunities (e.g., Hainan Boao Lecheng)	Missed early market access and real-world evidence generation opportunities

Building a Long-Term China Strategy

Successful foreign manufacturers treat China as a long-term market presence, not a one-time registration project:

• Build local KOL relationships early — they are critical for clinical trials, market adoption, and navigating the healthcare system
• Understand the reimbursement landscape. China's DRG payment reform and volume-based procurement (VBP) program have reshaped device pricing. A registered device without viable reimbursement has limited commercial value.
• Monitor provincial policies. Provincial and municipal authorities significantly influence hospital procurement, pricing, and market access.
• Plan your portfolio strategy. Consider starting with a Class II device to build experience before tackling Class III.
• Invest in post-market infrastructure. The MAH bears legal responsibility — NMPA inspections will test whether the MAH has adequate oversight.

Volume-Based Procurement (VBP) and Reimbursement: The Commercial Reality

Registration is only half the battle. China's reimbursement and procurement landscape has undergone dramatic changes that directly affect whether a registered device can achieve commercial viability.

Volume-Based Procurement (VBP):

China's National Healthcare Security Administration (NHSA) has aggressively expanded volume-based procurement (also called centralized procurement or "Jizhong Caigou") for medical devices and consumables. VBP works by pre-committing bulk purchase volumes across hospitals in exchange for significant price reductions. The impact has been dramatic:

• Coronary stents saw average price reductions of over 90% in the first national VBP round
• Orthopedic implants (hip, knee, spine) have experienced 50-85% price reductions
• The NHSA aims to cover approximately 80% of medical device expenditure through VBP
• As of 2025, six rounds of national medical device/consumable VBP have been completed, with additional rounds planned for 2026
• VBP rollout occurs province-by-province, meaning the impact on individual companies may be gradual rather than sudden
• Foreign manufacturers have seen margin compression across multiple categories, with some companies (such as in the intraocular lens segment) seeing revenues decline significantly

DRG/DIP Payment Reform:

• Diagnosis-Related Groups (DRG): Hospitals are paid a fixed amount per case based on diagnosis grouping, rather than fee-for-service. This creates pressure on hospitals to use lower-cost devices
• Diagnosis-Intervention Packet (DIP): Similar to DRG but based on disease score and point values, forming standardized per-case payments
• These reforms mean that even a registered, high-quality device may face limited adoption if hospitals cannot recover its cost within the DRG/DIP payment bracket

Government procurement restrictions (2025):

• China's Ministry of Finance has implemented measures restricting certain foreign manufacturers from participating in government procurement tenders for specific device categories, particularly in high-value segments where the contract value exceeds certain thresholds
• Some provinces have placed caps on the proportion of imported devices hospitals can procure in certain categories
• These policies reflect China's broader strategy to promote domestic innovation and reduce dependence on imported medical technology

Commercial planning imperative: Factor VBP pricing pressure and DRG/DIP constraints into your market entry business case from the outset. A device that achieves NMPA registration but cannot compete on price within the VBP framework or fit within DRG payment brackets may have limited commercial potential. Companies with strong innovation pipelines and products that address genuinely unmet clinical needs are best positioned to navigate these headwinds.

Additional IVD Considerations

Foreign IVD manufacturers face unique challenges beyond the IVD registration framework described above. Many assays must be evaluated using NIFDC national reference standards (which may differ from WHO materials), and clinical performance evaluation requires Chinese clinical samples. Reagent-instrument system registration creates sequencing dependencies — both the reagent and its instrument platform must be registered, which can add years if not planned carefully. China's domestic IVD industry (Mindray, Snibe, Maccura, Autobio) has strong positions in routine segments, creating pricing pressure through volume-based procurement.

New IVD Classification Catalog (Effective January 1, 2025)

In May 2024, the CMDE released a new IVD Classification Catalog that came into effect on January 1, 2025, replacing the existing catalog. Key changes:

• Structured coding format: IVD reagents are now assigned a primary code (6840-XX) and a secondary sub-category code (XX-XXXX), selected based on the product's intended use and specific diagnostic function
• First-time registrations: Starting January 1, 2025, all first-time IVD registration applications must use the new Classification Catalog codes
• Existing registrations: For renewal (extension) applications accepted before January 1, 2025 but not yet approved, review continues under the original catalog classification
• Impact on manufacturers: Companies with IVD products in development should confirm their new classification code and ensure their regulatory strategy aligns with the updated catalog. Some products may see classification changes that affect their registration pathway

IVD Market Outlook

China's IVD market is projected to reach $23.81 billion by 2030 (growing at 5.01% CAGR from 2025-2030), driven by chronic disease prevalence, technology advancement, and demographic aging. Key growth areas include high-end diagnostic platforms, molecular diagnostics, genetic testing, and companion diagnostics — segments where foreign manufacturers still hold competitive advantages despite domestic competition.

Looking Ahead

China's medical device regulatory system is at an inflection point. The 2021 reforms established a modernized legal foundation. The 2024-2026 reforms are building on it with practical measures to reduce barriers for foreign manufacturers and accelerate access to innovative devices. The direction is encouraging: greater acceptance of foreign data and testing, expanded expedited pathways, real-world evidence frameworks, and increasing international harmonization. But the pace of change is incremental, and a gap remains between policy as written and practice as experienced.

The manufacturers that succeed in China invest in understanding the system rather than fighting it, build strong local partnerships, plan for realistic timelines, engage CMDE early and often, and treat China as a strategic market — not an afterthought. The regulatory reforms of 2024-2026 have made market entry more feasible than at any point in the past decade. But the process still demands expertise, planning, and sustained commitment. There are no shortcuts. There is only preparation.